Boom in weight-loss drugs could lead to drop in beer sales, Heineken warns British pubs

Heineken has alerted UK bars about potential declines in beer sales due to the rising use of weight-loss drugs like GLP-1, which may reduce alcohol consumption. The company suggested strategies such as promoting smaller servings and low-alcohol options to adapt to changing consumer habits. Research indicates that GLP-1 users are opting for smaller drinks and premium products, reflecting broader market trends. While other beverage companies like Diageo and Carlsberg downplay the impact of these drugs on consumption, surveys show a decrease in drinking among GLP-1 users. Heineken reported significant beer sales in the UK, with low-alcohol products making up a small fraction.